Key clinical point: Omalizumab improved symptoms in people with chronic rhinosinusitis with nasal polyps.
Major finding: Sino-nasal outcome test scores improved 23.3 points in treated patients (P = .0001).
Study details: Subset analysis of 151 patients in the POLYP1 and POLYP2 Phase 2 trials of omalizumab.
Disclosures: Genentech sponsored the subset analysis. Hoffman-La Roche, Genentech’s parent company, is the sponsor of the POLYP1 and POLYP2 clinical trials. Dr. Corren is principal investigator of POLYP1 and disclosed financial relationships with Genentech.
Corren J et al. AAAAI Session 4608, Abstract 813.